ភាគហ៊ុន Moderna នៅតែជាជម្រើសដ៏ល្អសម្រាប់អ្នកវិនិយោគរយៈពេលវែង៖ អ្នកវិភាគ

ម៉ូនឌីណា Inc (NASDAQ: MRNA) has taken a big hit over the past seven weeks, which, as per an Oppenheimer analyst, is a fantastic opportunity for the long-term investors.

Reasons to own the Moderna stock

At a price-to-earnings multiple of just over four, the biotech firm is quite attractive in terms of valuation. But Hartaj Singh is bullish on the “fundamental” story here as well.

តើអ្នកកំពុងស្វែងរកព័ត៌មានរហ័សព័ត៌មានជំនួយក្តៅនិងការវិភាគទីផ្សារមែនទេ?

ចុះឈ្មោះសម្រាប់ព្រឹត្តិប័ត្រ Invezz ថ្ងៃនេះ។

ព្រឹកនេះនៅលើកញ្ចក់ទូរទស្សន៍ CNBC “ Squawk នៅតាមផ្លូវ”, he recommended that investors buy Moderna stock despite the near-term challenges.

They’re literally the leader in mRNA therapeutics. Moderna will most likely solve very complex diseases with its mRNA therapeutics going forward. They’re in the lead in manufacturing, pre-clinical and clinical development.

Singh is bullish on Moderna even after New York បានបញ្ចប់ the vaccine mandate for private sector and student athletes on Tuesday.

Moderna is a five-to-ten-year story

ក្នុងរបស់ខ្លួន ត្រីមាសរាយការណ៍ចុងក្រោយ, the Massachusetts-headquartered company took a $500 million hit on expiring COVID shots. The Oppenheimer analyst agrees such challenges will continue in the near-term (six to eighteen months) but said:

If you’re a believer of mRNA therapeutics being a fairly large segment ($100 billion to $150 billion) of therapeutics sales five or ten years from now, you should keep owning Moderna and maybe even buy some on extreme dips.

Singh has confidence in the management team at Moderna as well. Despite the post-COVID struggles, the Nasdaq-listed firm reported better-than-expected profit and revenue for its Q2 in August.

Wall Street has a consensus “overweight” rating on the ភាគហ៊ុនទំនើប ដូច​គ្នា។